Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum

Not Applicable

Recruiting

• Conditions: Pyoderma Gangrenosum
• Interventions: Procedure: Platelet rich plasma therapy

• Registration Number: NCT05984654
• Lead Sponsor: Ohio State University

Brief Summary

Pyoderma gangrenosum (PG) is a chronic inflammatory condition with severe painful ulcers. We hypothesize that Platelet-rich plasma(PRP) therapy derived from patient's own blood has a high concentration of endogenous growth factors, which will activate the wound-healing cascade stimulating formation of new blood vessels and collagen in PG ulcers.The goal of this study is to evaluate the efficacy and safety of autologous Platelet rich Plasma(PRP) therapy for the treatment of chronic Pyoderma Gangrenosum(PG). Researchers will also compare the efficacy of PRP therapy when used as a topical solution versus injections in and around the target ulcer/s.

Detailed Description

This is a prospective, randomized split-ulcer controlled trial that will enroll 10 adult patients with chronic pyoderma gangrenosum. In each participant, up to three separate ulcerations will be randomized into 3 comparative groups in 1:1:1 ratio to either receive monthly intralesional PRP injections or topical PRP therapy at 0, 4, 8, and 12 weeks while the third target ulcer will receive standard wound care only. In the event that only two ulcerations are present, they will be randomized to 1:1 standard care vs topical and intralesional PRP. All other ulcers, if any, will receive standard wound care during the study period. Participants will be followed up for 4 weeks after the completion of treatment period. The primary endpoint for this study will be the composite proportion of the target ulcers achieving either complete resolution or 50% reduction in the surface area at week 12.

Study Timeline

• Study First Submitted: 2023-08-02
• Study First Submitted QC: 2023-08-02
• Study First Posted: 2023-08-09
• Study Start: 2024-05-28
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-16
• Last Update Posted: 2024-07-17
• Primary Completion: 2026-12-30
• Study Completion: 2027-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Have given written informed consent before participating in any study-specific activity.
2. Have a clinical diagnosis of classic PG as determined by the principal investigator based on results from clinical, histological, and laboratory assessments.
3. Have at least 2 PG ulcer characterized by 'item a' AND 3/5 features in 'item b' OR 2/5 features in 'item b' with support from one of the conditions listed in c. a. Stable or increasing size within 2 months preceding screening by patient report or documentation. b. Features such as violaceous border, undermining, cribriform scarring, pustules, peristomal location. c. Identifiable secondary systemic condition, such as IBD, arthritis, MGUS, noncancerous hematologic disease, streptococcal carriage, levamisole-tainted cocaine, Bruton's agammaglobulinemia.
4. Have at least two PG target ulcers that have an area = 2 cm2 and = 200 cm2 at screening.
5. Age at least 18 years at screening.
6. A negative pregnancy test (for females of childbearing potential) at both screening and at Day 0.
7. PARACELSUS Score for pyoderma gangrenosum of 10 or greater.

Exclusion Criteria

1. Any condition (e.g., psychiatric illness, severe alcoholism, or drug abuse) or situation that may compromise the ability of the subject to give written informed consent, may put the subject at significant risk, may jeopardize the subject's safety after treatment, may confound the study results, or may interfere significantly with the subject's participation in the study.

2. History of malignancy within 2 years of screening other than carcinoma in situ of the cervix or adequately treated, non-metastatic, squamous, or basal cell carcinoma of the skin.

3. History of seropositivity for HIV antibody; active or carrier status of hepatitis B [surface antigen (HBsAg) positive, or core antibody (anti-HBc) positive with negative surface antibody]; active hepatitis C (i.e., not treated or not cleared spontaneously, as confirmed by HCV PCR).

4. Patients with hemodynamic instability, bleeding disorders, and/or platelet dysfunction syndrome.

5. A complete blood count will be performed for each participant at the beginning of the study and those with serum hemoglobin concentration <11 g/ dL or hematocrit <34% or platelet count<1, 00000/ml will be excluded from the study.

6. Patients with uncontrolled secondary systemic disease in the opinion of the investigator.

7. Systemic infection or active local infection requiring oral antibiotics within 2 weeks of Day 0.

8. History of the following treatments:

   1. Patients taking anticoagulant medication.
   2. Changes (addition, discontinuation, or changes in dose) in immunosuppressive medication (including cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, apremilast, dapsone, or corticosteroids) and biologics (Anti-TNF or other biologic therapies) within 2 months of Day 0.
   3. Systemic corticosteroids > 20 mg per day (prednisone or prednisone equivalent) within 8 weeks of Day 0 or change in dose within 4 weeks of Day 0. Steroids may be tapered (although not increased above the Day 0 dose) during the trial as determined by the principal investigator.
   4. Intralesional corticosteroids within 8 weeks of day 0; topical immunomodulators are also not permitted.
   5. Systemic antibiotics within 2 weeks of Day 0.
   6. Hyperbaric treatment within 4 weeks of Day 0.
   7. Investigational drug or investigational device within 4 weeks of Day 0.
   8. Other treatments not described above should be maintained at a stable dose and frequency throughout the study as best as possible.

9. Major, general surgery within 3 months of screening, or anticipated general surgery during the study period.

10. Pregnancy plans to become pregnant during the study, delivery within 3 months of screening, or breastfeeding.

11. If previous use of cyclosporine or systemic corticosteroids, failure to have any stabilization/response is exclusionary. This potentially indicates the disease is not PG.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Target ulcer Group 1(Injectable PRP)	Platelet rich plasma therapy	Under aseptic conditions, 2 mL of autologous PRP will be injected with 30 G needle at multiple sites in and around target ulcer approximately 1.5 cm apart at 0, 4, 8, and 12 weeks after local anesthesia.
Target ulcer Group 2(Topical PRP)	Platelet rich plasma therapy	Under aseptic conditions, 2 mL of autologous PRP will be applied topically followed by a Platelet poor plasma solution soaked dressing on the second target ulcer at 0, 4, 8, and 12 weeks.

Primary Outcome Measures

Name	Time	Method
Proportion of ulcers with complete healing or 50 % area reduction	12 weeks	Primary outcome will be the composite proportion of the target ulcers achieving either complete resolution or 50% reduction in the surface area at week 12 after treatment with either intralesional injectable or topical platelet-rich plasma therapy as compared to standard treatment

Secondary Outcome Measures

Name	Time	Method
Patient pain perception	Week 12 and week 16	Analysis of change in patient pain perception using 10-point visual analog scale (VAS) from baseline to week 12 and week 16. This is a 10 point scale with higher scores indicating more severe pain.
Change in quality of life	Week 12 and week 16	Analysis of change in patient quality of life using the dermatology life quality index (DLQI) from baseline to week 12 and week 16.
Patient Global Assessment (PGA) change	Week 12 and week 16	Analysis of change Patient Global Assessment (PGA) from baseline until baseline to week 12 and week 16
Total surface area change	Week 12 and week 16	Analysis of change in total surface area of target/total ulcers from baseline to week 12 and week 16
Investigator Global Assessment (IGA) change	Week 12 and week 16	Analysis of change Investigator Global Assessment (IGA) x maximum wound dimension from baseline until baseline to week 12 and week 16

Trial Locations

Locations (1)

The Ohio State University Wexner Medical Center; 🇺🇸 Columbus, Ohio, United States